LRRC15 and neoplasm: Always using transgenic mice models, Krishnamurty and colleagues selectively depleted the LRRC15+ CAF subpopulation in PDAC, and this was sufficient to significantly slow tumor growth and restore CD8+ T cell functions, increasing response to immunotherapy [31].